Navigation Links
Photos: Sentara Joins 4 U.S. Hospitals in International 'TARGIT' Breast Cancer Trial
Date:10/6/2008

- TARGIT Procedure May Eliminate 6 Weeks of Radiation Therapy - Event: Watch Single-Dose Radiation Treatment over the Internet Wednesday, October 22, 2008, 3 - 4 p.m. by visiting http://www.sentara.com/explorehealth

HAMPTON, Va., Oct. 6 /PRNewswire/ - Questions raced through Vela Cross' mind when she was diagnosed with breast cancer in May. Would she have the tumor removed or her entire breast? How about radiation or chemotherapy?

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/sentara/35294/

With doctors at Sentara CarePlex Hospital involved in the international TARGIT Trial, Cross became the first East Coast patient to receive this revolutionary treatment option.

Sentara CarePlex Hospital in Hampton, Virginia is among five U.S. centers and 22 worldwide enrolling patients in this study open to early-stage breast cancer patients. The study evaluates the effectiveness of an investigational single-dose internal radiation treatment compared with conventional external radiation.

The TARGIT Trial, which stands for TARGeted Intraoperative-radiation Therapy, could eliminate the need for six weeks of daily radiation.

"Regular radiation would have really interrupted my life," says Cross.

"Some women consider a mastectomy rather than facing weeks of conventional radiation," says surgical oncologist Dr. Richard Hoefer. "We hope our participation offers women another option," he continues.

Half of trial participants get the investigational one-time dose of radiation through an applicator placed in the tumor cavity. The radiation is targeted to breast cells with the highest risk of cancer recurrence-those that directly surrounded the tumor. Other trial participants receive 6-8 weeks of external radiation.

Equipment involved in this study was cleared by the U.S. FDA as safe and effective; trials at Sentara are subject to rigorous approvals.

"This study could significantly change the way we care for early-stage breast cancer patients," says Dr. Michael Miller, medical director of CarePlex Hospital's radiation oncology department.

TARGIT is a randomized phase III study, enrolling post-menopausal women at least 45 years old with single-site invasive breast cancer measuring less than 3 centimeters. For a patient to receive the single-dose radiation, they must be a candidate for the TARGIT Trial. Other considerations include type of cancer, tumor size, and lymph node involvement. To learn more, call 757-594- 1939 or visit http://www.sentara.com/cancer.


'/>"/>
SOURCE Sentara CarePlex Hospital
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
2. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
3. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
4. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
5. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
6. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
11. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... ), a developer of a new generation of ... positive overall survival results for Paclical/Apealea in the ... 789 patients with epithelial ovarian cancer. These preliminary ... Paclical/Apealea in combination with carboplatin versus Taxol in ...
(Date:4/27/2016)... , April 27, 2016 At ... the launch of a Phase 2 clinical study of ... in patients undergoing cochlear implantation (CI) surgery. This large, ... in Germany and ... middle ear at the time of surgery. "Despite advances ...
(Date:4/26/2016)... , April 26, 2016 US ... forecast to expand 4.9 percent annually to $27.6 ... other healthcare facilities to decrease rates of healthcare-associated ... prevention supplies, equipment, and services.  Although declining, the ... significantly above targeted levels set by the CDC.  ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 29, 2016 , ... Our bodies are bombarded daily by environmental and lifestyle ... these stressors is to adopt a more healthful diet, but too many people think ... certified Holistic Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... student loans more flexibility in repaying their loans, more information about their loan ... time when total outstanding student loan debt, including federal and private loans, has ...
(Date:4/29/2016)... ... 29, 2016 , ... Spine Team Texas, a comprehensive spine physician group specializing ... their physicians has been invited to be a featured speaker at the Texas Society ... on April 30, 2016. , Dr. R. Scott McPherson, a physical medicine and ...
(Date:4/29/2016)... ON (PRWEB) , ... April 29, 2016 , ... ... and the Canadian Celiac Association (CCA), is pleased to announce the launch of ... gluten-free products, nutritional articles, recipes, and more. The purpose of the GFCP ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Reltok ... devices and products for the head and neck/ear, nose and throat specialty, has added ... , The KOTLER NASAL AIRWAY™ is a newly patented safety device secured ...
Breaking Medicine News(10 mins):